1-15 of 15
Jane Estell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H Kerridge, Jane Estell, Craig wallington-Gates, Anna Kalff, Flora Yuen, Andrew Spencer
Journal: Blood
Blood (2022) 140 (Supplement 1): 10174–10176.
https://doi.org/10.1182/blood-2022-170697
Published: 2022
Journal Articles

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Torben Plesner, Simon J Harrison, Hang Quach, Cindy H. Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Teiko Sumiyoshi, Karen Miller, Eunpi Choi, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 2755.
https://doi.org/10.1182/blood-2021-147418
Published: 2021
Journal Articles

The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC)

Tishya Indran, Michael Swain, Jacqueline Widjaja, Flora Yuen, Hang Quach, Wojt Janowski, Anna Hutchinson, Craig Thomas Wallington-Beddoe, Jane Estell, Ian H Kerridge, Andrew Spencer
Journal: Blood
Blood (2021) 138 (Supplement 1): 3884.
https://doi.org/10.1182/blood-2021-150444
Published: 2021
Journal Articles

Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H Kerridge, Jane Estell, Wojt Janowski, Craig Thomas Wallington-Beddoe, Anna Kalff, Flora Yuen, Andrew Spencer
Journal: Blood
Blood (2021) 138 (Supplement 1): 1665.
https://doi.org/10.1182/blood-2021-152102
Published: 2021
Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Hang Quach, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Je-Jung Lee, MD PhD, Nichloas Murphy, MBBS, FRACP, FRCPA, Jae Hoon Lee, MD PhD, Kim Kihyun, MD, Jane Estell, FRACP, Noemi Horvath, MB ChB FRACP FRCPA, Richard Eek, FRACP., Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, Rajeev Rajagopal, FRACP, Soo-Mee Bang, MDPhD, Jeffrey SY Huang, MD, PhD, Yoon Sung Soo, MD PhD, Belinda Butcher, BSci, MBiostat, PhD, Brian G.M. Durie, MD, Wee Joo Chng, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-139174
Published: 2020
Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor

Katja C. Weisel, MD, Pieter Sonneveld, Maria-Victoria Mateos, Vania T.M. Hungria, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Maria Krevvata, PhD, Sonali Trivedi, Xiang Qin, Huiling Pei, PhD, Jon Ukropec, PhD, Rachel Kobos, MD, Ming Qi, MD PhD, Ajay K Nooka, MDMPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 3192.
https://doi.org/10.1182/blood-2019-123527
Published: 2019
Journal Articles

Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor

Maria-Victoria Mateos, MD PhD, Pieter Sonneveld, MD PhD, Vania T. M. Hungria, MD PhD, Ajay K Nooka, MD MPH, Jane Estell, FRACP, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD PhD, Eva Medvedova, MD, Katja Weisel, MD, Christopher Chiu, PhD, Jordan M. Schecter, Himal Amin, Xiang Qin, Ming Qi, Andrew Spencer, MBBS, FRACP, FRCPA, DM
Journal: Blood
Blood (2018) 132 (Supplement 1): 3270.
https://doi.org/10.1182/blood-2018-99-112554
Published: 2018
Journal Articles

Pomalidomide Alone or in Combination with Low Dose Dexamethasone As Maintenance Following Induction with Pomalidomide and Low Dose Dexamethasone in Relapsed and Refractory Myeloma (ALLG MM14)

Anna Kalff, MBBS, Nola Kennedy, John Reynolds, PhD, Hang Quach, MDFRACP,FRCPA,MBBS, Phoebe Joy Ho, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, James M. D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Jane Estell, FRACP, Andrew Spencer, MBBS, MD FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 1986.
https://doi.org/10.1182/blood-2018-99-118231
Published: 2018
Journal Articles

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

Ola Landgren, MD PhD, Michele Cavo, MD, Ajai Chari, MD, Yael C Cohen, MD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter M. Voorhees, MD, Jane Estell, FRACP, Irwindeep Sandhu, MDFRCPC, Matthew Jenner, Catherine Williams, Niels WCJ van de Donk, MD PhD, Meral Beksac, MD, Hartmut Goldschmidt, MD, Philippe Moreau, Steven Kuppens, Rajesh Bandekar, Tobias Neff, Annelore Cortoos, MD, Pamela L Clemens, PhD, Ming Qi, Homer Adams, III, PhD, Craig C Hofmeister, MDMPH
Journal: Blood
Blood (2018) 132 (Supplement 1): 1994.
https://doi.org/10.1182/blood-2018-99-113467
Published: 2018
Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Hang Quach, MDFRACP,FRCPA,MBBS, Simon J. Harrison, MBBS,MRCP,FRCPath,FRACP,PhD, Slavisa Ninkovic, MBBS FRACP FRCPA, Jane Estell, MBBS FRACP, Noemi Horvath, MBBS FRACP FRCPA, Nick Murphy, MBBS FRACP FRCPA, Richard Eek, MBCHB, Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rajeev Rajagopal, Akash Kalro, MD, Robyn Hemme, Belinda Butcher, BSc(Hons) MBiostat PhDCMPP AStat, Tracey Gerber, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Brian GM Durie, MD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 1955.
https://doi.org/10.1182/blood-2018-99-111434
Published: 2018
Journal Articles

Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

Gilles Andre Salles, MD PhD, John Francis Seymour, MBBS, Pierre Feugier, MD, Fritz Offner, MDhD, Armando Lopez-Guillermo, David Belada, MD PhD, Luc Xerri, MD PhD, Reda Bouabdallah, MD, John Catalano, Pauline Brice, MD, Corinne Haioun, Alejandro Martín, MD PhD, Lars Moller Pedersen, Alain Jacques Delmer, MD, David Simpson, MBChB, Sirpa Leppa, MD, Pierre Soubeyran, MD PhD, Rene-Olivier Casasnovas, MD, Tanin Intragumtornchai, MD, Vincent Ribrag, Maria Gomes Silva, Emmanuelle Nicolas-Virelizier, MD, Thomas Lister, MD, Jane Estell, Gustavo Milone, MD, Anne Sonet, MD, Julie Assemat, Harald Zeuner, Bertrand Coiffier, MD PhD, Herve Tilly
Journal: Blood
Blood (2017) 130 (Supplement 1): 486.
https://doi.org/10.1182/blood.V130.Suppl_1.486.486
Published: 2017
Journal Articles

Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Castor

Andrew Spencer, MD, Vania T M Hungria, MD PhD, Maria-Victoria Mateos, MD, Ajay Nooka, MDMPH, Jane Estell, Wolney G Barreto, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Piruntha Thiyagarajah, William Deraedt, Christopher Chiu, Jordan Schecter, Katja C. Weisel
Journal: Blood
Blood (2017) 130 (Supplement 1): 3145.
https://doi.org/10.1182/blood.V130.Suppl_1.3145.3145
Published: 2017
Journal Articles

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

Craig C Hofmeister, MDMPH, Ajai Chari, Yael Cohen, Andrew Spencer, MD, Peter M. Voorhees, MD, Jane Estell, Christopher P. Venner, Irwindeep Sandhu, Matthew W Jenner, Cathy Williams, Michele Cavo, MD, Niels WCJ Van De Donk, Meral Beksac, Steven Kuppens, Rajesh Bandekar, Tobias Neff, Christoph Heuck, Ming Qi, Hartmut Goldschmidt, MD, Ola Landgren, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 510.
https://doi.org/10.1182/blood.V130.Suppl_1.510.510
Published: 2017
Journal Articles

Discovery and Validation of a Simplified Scoring System (the PRIMA-Prognostic Index) in De Novo Follicular Lymphoma Treated Initially with Immunochemotherapy

Emmanuel Bachy, Matthew J Maurer, MS, Thomas M Habermann, MD, Benedicte Gelas Dore, Delphine Maucort-Boulch, Jane Estell, E. Van Den Este, Reda Bouabdallah, MD, Andrew L Feldman, MD, Joan Bargay, MD PhD, Alain Jacques Delmer, MD, Susan L Slager, PhD, Maria Gomes Silva, Olivier Fitoussi, MD, David Belada, MD PhD, Herve Maisonneuve, MD, Tanin Intragumtornchai, MD, Stephen M Ansell, MD PhD, Thierry Lamy, Pr, MD PhD, Peggy Dartigues-Cuillères, MD, Brian K Link, MD, John F Seymour, MBBS, PhD, James R. Cerhan, MD PhD, Gilles Salles, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 413.
https://doi.org/10.1182/blood.V130.Suppl_1.413.413
Published: 2017
Journal Articles

Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor

Maria-Victoria Mateos, MD PhD, Jane Estell, B.MD(Honours), FRACP, FRCPA, Wolney Barreto, PhD, Paolo Corradini, MD, Chang-Ki Min, MD, Eva Medvedova, MD, Ming Qi, Jordan Schecter, Himal Amin, Xiang Qin, William Deraedt, Tineke Casneuf, Christopher Chiu, A. Kate Sasser, Ajay Nooka, MD MPH
Journal: Blood
Blood (2016) 128 (22): 1150.
https://doi.org/10.1182/blood.V128.22.1150.1150
Published: 2016